Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Tetravalent DR5 agonist. Randomized chondrosarcoma trial completed (Oct 2025); FDA accepted BLA for filing in conventional chondrosarcoma (Jun 2026). Two new CRC Phase 1 cohorts initiated Q2 2026. FDA meeting planned Q4 2026 to discuss 1L registration path.
INBRX-106
Phase 2 · Active
Target OX40
Indications
Head and neck squamous cell carcinoma(Phase 2)
Non-small cell lung cancer(Phase 2)
Status note Hexavalent OX40 agonist. Randomized 1L Phase 2 portion of HexAgon study (with pembrolizumab) in PD-L1+ metastatic/unresectable recurrent HNSCC reported interim results May 2026; also being investigated in NSCLC.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.